The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained

Results from the Shared Equal Access Regional Cancer Hospital Database

Ryan S. Turley, Martha Kennedy Terris, Christopher J. Kane, William J. Aronson, Joseph C. Presti, Christopher L. Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

OBJECTIVE: To test the hypothesis that the association between prostate size and risk of Gleason grade upgrading varies as a function of sampling. PATIENTS AND METHODS: We examined the association between pathological prostate weight, prostate biopsy scheme and Gleason upgrading (Gleason ≥7 at radical prostatectomy, RP) among 646 men with biopsy Gleason 2-6 disease treated with RP between 1995 and 2007 within the Shared Equal Access Regional Cancer Hospital Database using logistic regression. In all, 204 and 442 men had a sextant (six or seven cores) or extended-core biopsy (eight or more cores), respectively. Analyses were adjusted for centre, age, surgery, preoperative prostate-specific antigen level, clinical stage, body mass index, race, and percentage of cores positive for cancer. RESULTS: In all, 281 men (44%) were upgraded; a smaller prostate was positively associated with the risk of upgrading in men who had an extended-core biopsy (P < 0.001), but not among men who had a sextant biopsy (P = 0.22). The interaction between biopsy scheme and prostate size was significant (P interaction = 0.01). CONCLUSIONS: These data support the hypothesis that the risk of upgrading is a function of two opposing contributions: (i) a more aggressive phenotype in smaller prostates and thus increased risk of upgrading; and (ii) more thorough sampling in smaller prostates and thus decreased risk of upgrading. When sampled more thoroughly, the phenotype association dominates and smaller prostates are linked with an increased risk of upgrading. In less thoroughly sampled prostates, these opposing factors nullify, resulting in no association between prostate size and risk of upgrading. These findings help to explain previously published disparate results of the importance of prostate size as a predictor of Gleason upgrading.

Original languageEnglish (US)
Pages (from-to)1074-1079
Number of pages6
JournalBJU International
Volume102
Issue number9
DOIs
StatePublished - Nov 1 2008

Fingerprint

Cancer Care Facilities
Neoplasm Grading
Prostate
Databases
Biopsy
Prostatectomy
Phenotype
Prostate-Specific Antigen
Body Mass Index
Logistic Models

Keywords

  • Biopsy cores
  • Prostate cancer
  • Prostate weight
  • Risk
  • Upgrading

ASJC Scopus subject areas

  • Urology

Cite this

The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained : Results from the Shared Equal Access Regional Cancer Hospital Database. / Turley, Ryan S.; Terris, Martha Kennedy; Kane, Christopher J.; Aronson, William J.; Presti, Joseph C.; Amling, Christopher L.; Freedland, Stephen J.

In: BJU International, Vol. 102, No. 9, 01.11.2008, p. 1074-1079.

Research output: Contribution to journalArticle

Turley, Ryan S. ; Terris, Martha Kennedy ; Kane, Christopher J. ; Aronson, William J. ; Presti, Joseph C. ; Amling, Christopher L. ; Freedland, Stephen J. / The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained : Results from the Shared Equal Access Regional Cancer Hospital Database. In: BJU International. 2008 ; Vol. 102, No. 9. pp. 1074-1079.
@article{c620dbcfc08e46b485bde0cc2c183a66,
title = "The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: Results from the Shared Equal Access Regional Cancer Hospital Database",
abstract = "OBJECTIVE: To test the hypothesis that the association between prostate size and risk of Gleason grade upgrading varies as a function of sampling. PATIENTS AND METHODS: We examined the association between pathological prostate weight, prostate biopsy scheme and Gleason upgrading (Gleason ≥7 at radical prostatectomy, RP) among 646 men with biopsy Gleason 2-6 disease treated with RP between 1995 and 2007 within the Shared Equal Access Regional Cancer Hospital Database using logistic regression. In all, 204 and 442 men had a sextant (six or seven cores) or extended-core biopsy (eight or more cores), respectively. Analyses were adjusted for centre, age, surgery, preoperative prostate-specific antigen level, clinical stage, body mass index, race, and percentage of cores positive for cancer. RESULTS: In all, 281 men (44{\%}) were upgraded; a smaller prostate was positively associated with the risk of upgrading in men who had an extended-core biopsy (P < 0.001), but not among men who had a sextant biopsy (P = 0.22). The interaction between biopsy scheme and prostate size was significant (P interaction = 0.01). CONCLUSIONS: These data support the hypothesis that the risk of upgrading is a function of two opposing contributions: (i) a more aggressive phenotype in smaller prostates and thus increased risk of upgrading; and (ii) more thorough sampling in smaller prostates and thus decreased risk of upgrading. When sampled more thoroughly, the phenotype association dominates and smaller prostates are linked with an increased risk of upgrading. In less thoroughly sampled prostates, these opposing factors nullify, resulting in no association between prostate size and risk of upgrading. These findings help to explain previously published disparate results of the importance of prostate size as a predictor of Gleason upgrading.",
keywords = "Biopsy cores, Prostate cancer, Prostate weight, Risk, Upgrading",
author = "Turley, {Ryan S.} and Terris, {Martha Kennedy} and Kane, {Christopher J.} and Aronson, {William J.} and Presti, {Joseph C.} and Amling, {Christopher L.} and Freedland, {Stephen J.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1111/j.1464-410X.2008.08015.x",
language = "English (US)",
volume = "102",
pages = "1074--1079",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained

T2 - Results from the Shared Equal Access Regional Cancer Hospital Database

AU - Turley, Ryan S.

AU - Terris, Martha Kennedy

AU - Kane, Christopher J.

AU - Aronson, William J.

AU - Presti, Joseph C.

AU - Amling, Christopher L.

AU - Freedland, Stephen J.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - OBJECTIVE: To test the hypothesis that the association between prostate size and risk of Gleason grade upgrading varies as a function of sampling. PATIENTS AND METHODS: We examined the association between pathological prostate weight, prostate biopsy scheme and Gleason upgrading (Gleason ≥7 at radical prostatectomy, RP) among 646 men with biopsy Gleason 2-6 disease treated with RP between 1995 and 2007 within the Shared Equal Access Regional Cancer Hospital Database using logistic regression. In all, 204 and 442 men had a sextant (six or seven cores) or extended-core biopsy (eight or more cores), respectively. Analyses were adjusted for centre, age, surgery, preoperative prostate-specific antigen level, clinical stage, body mass index, race, and percentage of cores positive for cancer. RESULTS: In all, 281 men (44%) were upgraded; a smaller prostate was positively associated with the risk of upgrading in men who had an extended-core biopsy (P < 0.001), but not among men who had a sextant biopsy (P = 0.22). The interaction between biopsy scheme and prostate size was significant (P interaction = 0.01). CONCLUSIONS: These data support the hypothesis that the risk of upgrading is a function of two opposing contributions: (i) a more aggressive phenotype in smaller prostates and thus increased risk of upgrading; and (ii) more thorough sampling in smaller prostates and thus decreased risk of upgrading. When sampled more thoroughly, the phenotype association dominates and smaller prostates are linked with an increased risk of upgrading. In less thoroughly sampled prostates, these opposing factors nullify, resulting in no association between prostate size and risk of upgrading. These findings help to explain previously published disparate results of the importance of prostate size as a predictor of Gleason upgrading.

AB - OBJECTIVE: To test the hypothesis that the association between prostate size and risk of Gleason grade upgrading varies as a function of sampling. PATIENTS AND METHODS: We examined the association between pathological prostate weight, prostate biopsy scheme and Gleason upgrading (Gleason ≥7 at radical prostatectomy, RP) among 646 men with biopsy Gleason 2-6 disease treated with RP between 1995 and 2007 within the Shared Equal Access Regional Cancer Hospital Database using logistic regression. In all, 204 and 442 men had a sextant (six or seven cores) or extended-core biopsy (eight or more cores), respectively. Analyses were adjusted for centre, age, surgery, preoperative prostate-specific antigen level, clinical stage, body mass index, race, and percentage of cores positive for cancer. RESULTS: In all, 281 men (44%) were upgraded; a smaller prostate was positively associated with the risk of upgrading in men who had an extended-core biopsy (P < 0.001), but not among men who had a sextant biopsy (P = 0.22). The interaction between biopsy scheme and prostate size was significant (P interaction = 0.01). CONCLUSIONS: These data support the hypothesis that the risk of upgrading is a function of two opposing contributions: (i) a more aggressive phenotype in smaller prostates and thus increased risk of upgrading; and (ii) more thorough sampling in smaller prostates and thus decreased risk of upgrading. When sampled more thoroughly, the phenotype association dominates and smaller prostates are linked with an increased risk of upgrading. In less thoroughly sampled prostates, these opposing factors nullify, resulting in no association between prostate size and risk of upgrading. These findings help to explain previously published disparate results of the importance of prostate size as a predictor of Gleason upgrading.

KW - Biopsy cores

KW - Prostate cancer

KW - Prostate weight

KW - Risk

KW - Upgrading

UR - http://www.scopus.com/inward/record.url?scp=53849102210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53849102210&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.08015.x

DO - 10.1111/j.1464-410X.2008.08015.x

M3 - Article

VL - 102

SP - 1074

EP - 1079

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -